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inflammatory  bowel  disease  (IBD),  are  not  limited  to  those 
mediated by  immune  cells,  but  also  include  those mediated 



















































































































Immunohistochemical staining of EPCR and TM in colons 
of normal and actively inflamed IBD patients. The panels 
show brown immunohistochemical staining for EPCR and 
TM in the microvasculature of colonic mucosa and submu-
cosa from histologically normal control (A and B), active 
IBD (C and D), and noninflamed IBD (E and F) tissues. 
Images are representative of 12 control, 14 UC, and 15 CD 
samples (original magnification, ×10). Red arrows indicate 
intestinal microvessels.
Figure 2
Localization of EPCR in IBD mucosa. Fluorescence micrographs of colonic mucosa 
microvessels in normal mucosa. (A–C) Staining for EPCR (green, A), von Willebrand 
factor (red, B), and nuclei (blue, C). (D) Merge (yellow) of panels A–C. (E and F) Binary 
mask of colocalization (white, E) and colocalization of panels B and E (F). Images are 
representative of 6 control, 7 CD, and 8 UC samples. Scale bars: 60 μm. 
research article
	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 117      Number 7      July 2007  1953
Results
Evidence for TM and EPCR downregulation in the IBD microvascula-
ture. In order to investigate the expression levels of TM and EPCR 





















































Effect of different cytokines on EPCR and TM 
expression by HIMECs. (A) HIMEC monolayers 
were left untreated (Baseline) or stimulated with 
TNF-α or IL-10 for 24 hours, after which cells 
were suspended and EPCR and TM expression 
measured by flow cytometry. Filled curve repre-
sents background signal from the isotype control. 
Values are representative of 6 separate experi-
ments. Numbers represent the net percentage of 
positive cells. (B) HIMEC monolayers were left 
untreated or stimulated with TNF-α for 24 hours, 
after which supernatants were collected for 
ELISA measurement of soluble EPCR and TM. 
Cellular mRNA was extracted for real-time PCR 
of EPCR and TM message levels. Values are rep-
resentative of 3 separate experiments. *P < 0.05, 
**P < 0.01 versus baseline.
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TNF-α–inflamed HIMECs exhibit a reduced capacity for PC activation. 
HIMEC monolayers were incubated 24 hours with or without TNF-α 
and assayed for their ability to support activation of PC by thrombin. 
Generation of aPC was measured using the chromogenic tripeptidyl-
pNA substrate S-2366; relative capacity for PC activation is presented 
as change in absorbance at 405 nm over time (mOD/min). Values are 
representative of 3 separate experiments. *P < 0.05 versus baseline.
Figure 5
Downregulation of VCAM-1 and ICAM-1 
by recombinant aPC in TNF-α–inflamed 
HIMECs. HIMEC monolayers were left 
untreated or stimulated with TNF-α in 
the presence or absence of recombinant 
human aPC. After 24 hours, cells were 
suspended and VCAM-1 and ICAM-1 
expression was measured by flow cytom-
etry. Filled curve represents background 
signal from the isotype control. Values are 
representative of 5 separate experiments. 
Numbers represent the net percentage of 
positive cells.
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Downregulation of chemokine pro-
duction by recombinant aPC in 
TNF-α–inflamed HIMECs. HIMEC 
monolayers were left untreated 
or stimulated with TNF-α in the 
presence or absence of recombi-
nant human aPC. After 24 hours, 
supernatants were collected, and 
ENA-78, IL-8, and MCP-1 were 
measured by ELISA. Values are 
representative of 5 separate exper-
iments. *P < 0.05 versus TNF-α 
without aPC.
Figure 7
Inhibition of T cell adhesion to TNF-α–inflamed HIMECs by recombinant 
aPC. HIMEC monolayers were left untreated or stimulated with TNF-α 
with or without recombinant human aPC. Calcein-labeled MOLT4 T cells 
were added to the HIMEC monolayers. Values are mean ± SEM of 4 
separate experiments. *P < 0.05 versus TNF-α without aPC.
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Dextran sodium sulfate (DSS) colitic mice exhibit a reduced capac-
ity for PC activation. Healthy and colitic mice (n = 3 per group) were 
injected i.v. with exogenous human PC. After 30 minutes, blood was 
collected into sodium citrate anticoagulant supplemented with benza-
midine to protect aPC from inhibition by endogenous irreversible inhibi-
tors. Using the immunocapture assay described in Methods, aPC was 
measured using the chromogenic tripeptidyl-pNA substrate S-2366; 
relative capacity for PC activation is presented as the change in absor-
bance at 405 nm over time. *P < 0.05 versus healthy mice.
Figure 9
Therapeutic effects of murine recombinant aPC administration. Animals undergoing DSS treatment were given daily i.v. injections of recombinant 
murine aPC (1 mg/kg; n = 10) or placebo (n = 12). Weight was monitored (A) as well as disease activity index (DAI) (B). After 10 days, mice were 
sacrificed, and colons were assessed for histological colitis (C and D). *P < 0.05, aPC versus placebo.
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aPC inhibits CAM expression, IL-8 production, and leukocyte adhesion 
to the endothelium in the intestine. Animals undergoing DSS treatment 
were given daily i.v. injections of recombinant murine aPC or placebo. 
After 10 days mice were sacrificed, and biopsies were collected for 
Western blot analysis for VCAM-1 and ICAM-1 (A) or organ culture for 
IL-8 measurement by ELISA (B). (C) Leukocyte–endothelial cell inter-
actions were assessed by intravital microscopy in 3 groups of animals: 
healthy mice (n = 5); DSS colitic mice treated for 10 days with placebo 
(n = 8); and DSS colitic mice treated for 10 days with daily i.v. injec-
tions of recombinant aPC (n = 6). For each animal, 3–6 unbranched 
venules were studied and the mean value was calculated. Leukocyte 
adhesion is expressed as the number of firmly adherent leukocytes 
to the endothelium per 100 μm of venule. *P < 0.05 versus placebo; 
**P < 0.001 versus healthy mice.
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